<DOC>
	<DOCNO>NCT01856309</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety efficacy CNTO 136 ( sirukumab ) participant rheumatoid arthritis ( RA ) unresponsive treatment modify antirheumatic drug ( DMARDs ) anti-TNF alpha agent .</brief_summary>
	<brief_title>Long-term Safety Efficacy Sirukumab Participants With RA Completing Studies CNTO136ARA3002 CNTO136ARA3003</brief_title>
	<detailed_description>This multicenter , long-term study sirukumab ( CNTO 136 ) conduct two group participant time ( parallel-group study ) . The maximum duration participation study 208 week , follow approximately 16 week safety efficacy follow-up administration final study agent injection sirukumab . Participant safety monitor throughout study .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Completed participation Studies CNTO136ARA3002 CNTO136ARA3003 Signed informed consent form ( ICF ) indicate understand purpose procedure require study willing participate study Signed informed consent form ( ICF ) pharmacogenetics research ( person 's gene may affect drug 's effect ) order participate optional pharmacogenetics component study . Refusal give consent component exclude participant participation clinical study Withdraws consent and/or discontinues participation study CNTO136ARA3002 CNTO136ARA3003 Is pregnant Has active diverticulitis Has condition , opinion investigator , would make participation best interest ( eg , compromise wellbeing ) participant could prevent , limit , confound protocolspecified assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Sirukumab</keyword>
	<keyword>CNTO 136</keyword>
	<keyword>CNTO136ARA3002</keyword>
	<keyword>SIRROUND-D</keyword>
	<keyword>CNTO136ARA3003</keyword>
	<keyword>SIRROUND-T</keyword>
	<keyword>SIRROUND-LTE</keyword>
</DOC>